NIH R01 · 2024
Imaging Feedback for Histotripsy Renal Tumor Ablation
PROJECT SUMMARY: Renal cell carcinoma (RCC) is the sixth most common cancer in the United States, with ~ 82k new diagnoses estimated for 2023. Surgery is the preferred option for initial management of RCC, but the number of patients who qualify is reduced each year due to the aging, comorbid population. Histotripsy is a noninvasive, focused ultrasound therapy used for tissue ablation via bubble activity, and is an attractive alternative to surgery. Indeed, a pilot clinical trial to test histotripsy for the treatment of RCC is scheduled for 2023. Standard B-mode ultrasound imaging is used to monitor histotripsy via the detection of hyperintense bubble pixels. In the kidney, histotripsy…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.